GSGert Schaart

Gert Schaart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gert Schaart has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial

    by Evi J. C. Koene, Vera B. Schrauwen-Hinderling, Jeremy Basset-Sagarminaga, Kim Brouwers, Yvonne M. H. Op Den Kamp-Bruls, Julian Mevenkamp, Florian Haans, Gert Schaart, Esther Kornips, Johanna A. Jorgensen, et al.


  • Open Access

    Prolonged β2-agonist treatment enhances muscle-specific glucose uptake in individuals with overweight and obesity: a randomized placebo-controlled trial

    by Pip M. G. Van Lier, Tineke van de Weijer, Froukje Vanweert, Kim Brouwers, Kevin M. R. Nijssen, Gert Schaart, Esther Moonen-Kornips, Sten M. M. van Beek, Sam Springer, Roel Wierts, et al.

    Impaired post-prandial skeletal muscle glucose uptake plays a pivotal role in the development of type 2 diabetes mellitus (T2DM), yet pharmacological strategies to enhance muscle glucose uptake are limited. Previous (pre)clinical research revealed that β 2 -adrenergic receptor (β2-AR) stimulation enhances glucose uptake, but its clinical relevance in individuals susceptible to developing T2DM is unknown. Here we determined in a double-blinded, placebo-controlled, crossover study (ClinicalTrials.gov-identifier: NCT04921306), the effects of a 4-week treatment with the β 2 -adrenergic agonist clenbuterol (40 μg/day) on insulin-stimulated glucose uptake in the quadriceps muscle (primary outcome) and brown adipose tissue (BAT) (secondary outcome) using 18 F-FDG PET-MRI during a hyperinsulinemic-euglycemic clamp in individuals with overweight or obesity (age: 40-70 years, BMI: 25-35 kg/m 2 ). A total of 14 participants were recruited and randomized. Insulin-stimulated glucose uptake tended to improve in vastus lateralis (15%, p = 0.072) and increased significantly in the hamstring (13%, p = 0.039) muscle, while BAT uptake (p = 0.720) remained unaffected. These findings suggest potential therapeutic benefits of β 2 -AR stimulation for improving muscle-specific glucose uptake in individuals with or at risk for developing diabetes.

  • Cold acclimation with shivering improves metabolic health in adults with overweight or obesity

    by Adam J. Sellers, Sten M. M. van Beek, Dzhansel Hashim, Rosalie Baak, Hannah Pallubinsky, Esther Moonen-Kornips, Gert Schaart, Anne Gemmink, Johanna A. Jörgensen, Tineke van de Weijer, et al.

    Cold acclimation increases insulin sensitivity, and some level of muscle contraction appears to be needed for provoking this effect. Here 15 men and (postmenopausal) women with overweight or obesity, the majority of whom had impaired glucose tolerance, were intermittently exposed to cold to induce 1 h of shivering per day over 10 days. We determined the effect of cold acclimation with shivering on overnight fasted oral glucose tolerance (primary outcome) and on skeletal muscle glucose transporter 4 translocation (secondary outcome). We find that cold acclimation with shivering improves oral glucose tolerance, fasting glucose, triglycerides, non-esterified fatty acid concentrations and blood pressure. Cold acclimation with shivering may thus represent an alternative lifestyle approach for the prevention and treatment of obesity-related metabolic disorders. ClinicalTrials.gov registration: NCT04516018.


  • Open Access

    The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals: a double‐blind, randomized, placebo‐controlled crossover study

    by Vera H. W. de Wit‐Verheggen, Froukje Vanweert, Juho Raiko, Viktor Liénard, Gert Schaart, Anne Gemmink, Emmani B. M. Nascimento, Matthijs K. C. Hesselink, Joachim E. Wildberger, Roel Wierts, et al.

    Objective: Insulin resistance is characterized by ectopic fat accumulation leading to cardiac diastolic dysfunction and nonalcoholic fatty liver disease. The objective of this study was to determine whether treatment with the peroxisome proliferator‐activated receptor‐α (PPARα) agonist ciprofibrate has direct effects on cardiac and hepatic metabolism and can improve insulin sensitivity and cardiac function in insulin‐resistant volunteers.Methods: Ten insulin‐resistant male volunteers received 100 mg/d of ciprofibrate and placebo for 5 weeks in a randomized double‐blind crossover study. Insulin‐stimulated metabolic rate of glucose (MRgluc) was measured using dynamic 18F‐fluorodeoxyglucose‐positron emission tomography (18F‐FDG‐PET). Additionally, cardiac function, whole‐body insulin sensitivity, intrahepatic lipid content, skeletal muscle gene expression, 24‐hour blood pressure, and substrate metabolism were measured.Results: Whole‐body insulin sensitivity, energy metabolism, and body composition were unchanged after ciprofibrate treatment. Ciprofibrate treatment decreased insulin‐stimulated hepatic MRgluc and increased hepatic lipid content. Myocardial net MRgluc tended to decrease after ciprofibrate treatment, but ciprofibrate treatment had no effect on cardiac function and cardiac energy status. In addition, no changes in PPAR‐related gene expression in muscle were found.Conclusions: Ciprofibrate treatment increased hepatic lipid accumulation and lowered MRgluc, without affecting whole‐body insulin sensitivity. Furthermore, parameters of cardiac function or cardiac energy status were not altered upon ciprofibrate treatment.


  • Open Access

    Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial

    by Sten M. M. van Beek, Yvonne M. H. Bruls, Froukje Vanweert, Ciarán E. Fealy, Niels J. Connell, Gert Schaart, Esther Moonen-Kornips, Johanna A. Jörgensen, Frédéric M. Vaz, Ellen T. H. C. Smeets, et al.

    β2-agonist treatment improves skeletal muscle glucose uptake and whole-body glucose homeostasis in rodents, likely via mTORC2-mediated signalling. However, human data on this topic is virtually absent. We here investigate the effects of two-weeks treatment with the β2-agonist clenbuterol (40 µg/day) on glucose control as well as energy- and substrate metabolism in healthy young men (age: 18-30 years, BMI: 20-25 kg/m2) in a randomised, placebo-controlled, double-blinded, cross-over study (ClinicalTrials.gov-identifier: NCT03800290). Randomisation occurred by controlled randomisation and the final allocation sequence was seven (period 1: clenbuterol, period 2: placebo) to four (period 1: placebo, period 2: clenbuterol). The primary and secondary outcome were peripheral insulin-stimulated glucose disposal and skeletal muscle GLUT4 translocation, respectively. Primary analyses were performed on eleven participants. No serious adverse events were reported. The study was performed at Maastricht University, Maastricht, The Netherlands, between August 2019 and April 2021. Clenbuterol treatment improved peripheral insulin-stimulated glucose disposal by 13% (46.6 ± 3.5 versus 41.2 ± 2.7 µmol/kg/min, p = 0.032), whereas skeletal muscle GLUT4 translocation assessed in overnight fasted muscle biopsies remained unaffected. These results highlight the potential of β2-agonist treatment in improving skeletal muscle glucose uptake and underscore the therapeutic value of this pathway for the treatment of type 2 diabetes. However, given the well-known (cardiovascular) side-effects of systemic β2-agonist treatment, further exploration on the underlying mechanisms is needed to identify viable therapeutic targets.


  • Open Access

    Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial

    by Anna Veelen, Charlotte Andriessen, Yvo Op Den Kamp, Edmundo Erazo-Tapia, Marlies de Ligt, Julian Mevenkamp, Johanna A. Jörgensen, Esther Moonen-Kornips, Gert Schaart, Russell Esterline, et al.


  • Top Cited Papers
    Open Access

    Impact of aging and exercise on skeletal muscle mitochondrial capacity, energy metabolism, and physical function

    by L. Grevendonk, N. J. Connell, C. McCrum, C. E. Fealy, L. Bilet, Y. M. H. Bruls, J. Mevenkamp, V. B. Schrauwen-Hinderling, J. A. Jörgensen, E. Moonen-Kornips, et al.

    The relationship between the age-associated decline in mitochondrial function and its effect on skeletal muscle physiology and function remain unclear. In the current study, we examined to what extent physical activity contributes to the decline in mitochondrial function and muscle health during aging and compared mitochondrial function in young and older adults, with similar habitual physical activity levels. We also studied exercise-trained older adults and physically impaired older adults. Aging was associated with a decline in mitochondrial capacity, exercise capacity and efficiency, gait stability, muscle function, and insulin sensitivity, even when maintaining an adequate daily physical activity level. Our data also suggest that a further increase in physical activity level, achieved through regular exercise training, can largely negate the effects of aging. Finally, mitochondrial capacity correlated with exercise efficiency and insulin sensitivity. Together, our data support a link between mitochondrial function and age-associated deterioration of skeletal muscle.


  • Open Access

    Resveratrol‐induced remodelling of myocellular lipid stores: A study in metabolically compromised humans

    by Nynke Polanen, Evelyn Zacharewicz, Marlies Ligt, Silvie Timmers, Esther Moonen‐Kornips, Gert Schaart, Joris Hoeks, Patrick Schrauwen, Matthijs K. C. Hesselink

    Resveratrol increases IMCL in type I muscle fibers originating primarily from an increase in number of lipid droplets rather than size.


  • Open Access

    L-carnitine infusion does not alleviate lipid-induced insulin resistance and metabolic inflexibility

    by Yvonne M. H. Bruls, Yvo J. M. Op Den Kamp, Esther Phielix, Lucas Lindeboom, Bas Havekes, Gert Schaart, Esther Moonen-Kornips, Joachim E. Wildberger, Matthijs K. C. Hesselink, Patrick Schrauwen, et al.

    Low carnitine status may underlie the development of insulin resistance and metabolic inflexibility. Intravenous lipid infusion elevates plasma free fatty acid (FFA) concentration and is a model for simulating insulin resistance and metabolic inflexibility in healthy, insulin sensitive volunteers. Here, we hypothesized that co-infusion of L-carnitine may alleviate lipid-induced insulin resistance and metabolic inflexibility. In a randomized crossover trial, eight young healthy volunteers underwent hyperinsulinemic-euglycemic clamps (40mU/m2/min) with simultaneous infusion of saline (CON), Intralipid (20%, 90mL/h) (LIPID), or Intralipid (20%, 90mL/h) combined with L-carnitine infusion (28mg/kg) (LIPID+CAR). Ten volunteers were randomized for the intervention arms (CON, LIPID and LIPID+CAR), but two dropped-out during the study. Therefore, eight volunteers participated in all three intervention arms and were included for analysis. L-carnitine infusion elevated plasma free carnitine availability and resulted in a more pronounced increase in plasma acetylcarnitine, short-, medium-, and long-chain acylcarnitines compared to lipid infusion, however no differences in skeletal muscle free carnitine or acetylcarnitine were found. Peripheral insulin sensitivity and metabolic flexibility were blunted upon lipid infusion compared to CON but L-carnitine infusion did not alleviate this. Acute L-carnitine infusion could not alleviated lipid-induced insulin resistance and metabolic inflexibility and did not alter skeletal muscle carnitine availability. Possibly, lipid-induced insulin resistance may also have affected carnitine uptake and may have blunted the insulin-induced carnitine storage in muscle. Future studies are needed to investigate this.